Search - tctmd.com

Displaying 41 - 60 of 120

Sort: Relevancy | Date

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Daily News

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

Caitlin E. Cox

October 16, 2019

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

News Daily News

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Caitlin E. Cox

August 12, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

Yael L. Maxwell

June 18, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Features

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

Caitlin E. Cox

May 01, 2019

Presentation

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

February 11, 2019

Advertisement

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

PAD Patients Undertreated With Statins Despite Elevated CV Risk

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Outcome Differences Between Men and Women With PAD: EUCLID Insights

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Microvascular Disease Quadruples Risk of Leg Amputation

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

TCTMD’s Top 10 Most Popular Stories for May 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content